We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...
DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...
TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent player in the biotechnology sector with a market capitalization of $77.1 billion and annual revenue of $ ...
FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...
In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...
FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...
The acceptance of the Dupixent (dupilumab; Sanofi, Regeneron) application in this indication may give hope to the approximately 27,000 adults in the U.S. living with bullous pemphigoid (BP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback